within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB15_RopeginterferonAlfa2b;

model RopeginterferonAlfa2b
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.0555555555555557e-08,
    adminDuration = 600,
    adminMass = 250 / 1000000,
    adminCount = 1,
    Vd = 0.0055,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>RopeginterferonAlfa2b</td></tr><tr><td>ATC code:</td><td>L03AB15</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>250</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.038</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ropeginterferon alfa-2b is a mono-pegylated, long-acting interferon-alpha used primarily in the treatment of polycythemia vera and other myeloproliferative neoplasms. It is currently approved for use in certain countries for treating polycythemia vera.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following subcutaneous administration in adult patients with polycythemia vera.</p><h4>References</h4><ol><li><p>Miyachi, N, et al., &amp; Qin, A (2021). Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. <i>Clinical drug investigation</i> 41(4) 391–404. DOI:<a href=\"https://doi.org/10.1007/s40261-021-01026-5\">10.1007/s40261-021-01026-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33725322/\">https://pubmed.ncbi.nlm.nih.gov/33725322</a></p></li><li><p>Huang, YW, et al., &amp; Wang, MX (2021). Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. <i>Advances in therapy</i> 38(9) 4756–4770. DOI:<a href=\"https://doi.org/10.1007/s12325-021-01863-y\">10.1007/s12325-021-01863-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34328630/\">https://pubmed.ncbi.nlm.nih.gov/34328630</a></p></li><li><p>Lin, HH, et al., &amp; Chen, PJ (2021). Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. <i>JGH open : an open access journal of gastroenterology and hepatology</i> 5(8) 929–940. DOI:<a href=\"https://doi.org/10.1002/jgh3.12613\">10.1002/jgh3.12613</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34386602/\">https://pubmed.ncbi.nlm.nih.gov/34386602</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L03AB15 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end RopeginterferonAlfa2b;
